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Objective To determine if topical ophthalmic diclofenac sodium 0.1% solution alters renal 
parameters in the domestic chicken, and to determine if the drug is detectable in plasma after 
topical ophthalmic administration. 
Animals Thirty healthy domestic chickens  
Procedures Over seven days, 6 birds were treated unilaterally with 1 drop of artificial tear 
solution (group 1), 12 birds were treated unilaterally (group 2) and 12 bilaterally (group 3) with 
diclofenac sodium 0.1% ophthalmic solution.  Treatments were provided for 7 days, every 12 
hours in all groups.  Pre- and post-treatment plasma samples from all birds were evaluated for 
changes in albumin, total protein, and uric acid.  Post-treatment samples of all birds were also 
analyzed by HPLC-MS for detection of diclofenac sodium.  
Results Changes in pre- and post-treatment plasma albumin were significant (P < 0.05) in 
groups 2 and 3, but not for group 1.  Pre- and post-treatment changes in total protein and uric 
acid pre- and post-treatment were not significant for any group.  Diclofenac sodium was not 
detectable (limit of detection = 0.10 ng/mL) in plasma samples from birds in group 1.  
Concentration of drug in group 3 was statistically greater than group 2 (P = 0.0008). 
Conclusions and Clinical Relevance Topical ophthalmic diclofenac sodium 0.1% administered 
every 12 hours in one or both eyes for 7 days is detectable in systemic circulation in the domestic 
chicken at 15 minutes post-administration, but did not cause overt changes in parameters used to 
monitor renal physiology.   
Key Words: avian, diclofenac, glomerulonephritis, nonsteroidal anti-inflammatory 
Abbreviations: 
HPLC-MS, high-performance liquid chromatography with mass spectrometry 
NSAID, nonsteroidal anti-inflammatory drug 
Diclofenac sodium 0.1% ophthalmic solution is a commercially available NSAID used to treat 
inflammation associated with ocular disease by inhibiting cyclooxygenase, the enzyme 
responsible for prostaglandin synthesis during uveitis.1,2 
Corticosteroids may also be used to treat ocular inflammation, however, topical corticosteroids 
are used cautiously in ophthalmic diseases due to potential side effects.3 In birds, topical 
ophthalmic corticosteroids use is further limited by systemic absorption and consequent potential 
immunosuppression.4 Side effects of topical ophthalmic NSAID therapy can include delayed 
wound healing, keratitis, and keratomalacia, but are generally considered more benign than 
effects of corticosteroids.5-10 Thus, topical NSAIDs are often preferred for chronic management 
of ocular inflammation in birds.  
Recently the use of diclofenac in some avian species has been investigated.  Multiple studies 
have evaluated the toxic effects of oral and injectable diclofenac in various avian species after a 
sharp decline in the population of Gyps vultures in South Asia after the birds ingested carrion 
from diclofenac-treated livestock.  These studies reported fatal renal disease and secondary 
visceral gout formation in the affected birds.11-20 Topical diclofenac sodium ophthalmic solution 
has been used in domestic and wild-caught birds for treatment of ocular inflammation without 
reported negative clinical side effects.21,22  However, following topical ophthalmic application 
the drug is absorbed into systemic circulation, creating a potential for systemic side effects.3,23,24  
To the authors’ knowledge, no studies have evaluated the bioavailability or hemodynamics of the 
drug following topical ophthalmic administration in avian species.  
The purpose of this study is to determine if topical ophthalmic diclofenac sodium 0.1% solution 
adversely affects renal function in the domestic chicken, and to determine if the drug is 
detectable in plasma after topical ophthalmic administration.  The authors hypothesized that a 
minor amount of diclofenac would reach detectable levels in plasma, but would not cause a 
significant change in the parameters used to monitor avian renal function. 
 
Materials and Methods 
Approval for this study was obtained from the Iowa State University Institutional Animal Care 
and Use Committee. The study was conducted in accordance with the Association for Research 
in Vision and Ophthalmology guidelines concerning the use of animals in ophthalmic and vision 
research. 
Thirty female domestic chickens (Gallus gallus domesticus) approximately 2 years of age with a 
mean weight of 1.46 ± 0.21 kg were acquired from a single laying farm.  Each bird received a 
brief ophthalmic examination with slit-lamp biomicroscopy.  The wing tag number for each bird 
was recorded prior to being randomly assigned a study number (1 – 30).  The flock was divided 
into 3 groups: control (Group 1, n = 6), unilateral treatment (Group 2, n = 12), and bilateral 
treatment (Group 3, n = 12) and allowed 48 hours to acclimate to the study environment.  
Throughout the study, each group was housed in a 1.2 x 2.4 meter cage that was elevated 30.5 
cm from the floor.  The atmosphere was maintained at 21oC with a 12-hour light:dark 
photoperiod.  All groups received identical feed and water sources ad libitum.   
On day 0, all birds were manually restrained for venipuncture of either the jugular or wing vein 
with a 25 gauge needle and 2.5 mL of whole blood was collected into a sodium heparin tube.  
Plasma was collected from the tubes after centrifugation (3,300 rpm x 10 minutes).  Each plasma 
sample was divided evenly into two additive-free 1.5mL blood collection tubes.  The samples 
were kept at -80oC until analysis.   
The animals were treated every 12 hours with either artificial tear solution (control) or diclofenac 
sodium 0.1% ophthalmic solution for 7 days.  Group 1 received 1 drop of artificial tear solution 
in both eyes, group 2 received 1 drop of diclofenac sodium 0.1% in the left eye, and group 3 
received 1 drop of diclofenac sodium 0.1% in both eyes.   
At the end of the treatment period, an additional 2.5 mL of blood was collected, as previously 
described, 15 minutes after administration of the final treatment.  Plasma was collected and 
stored via the previously described techniques.  After venipuncture, the birds were immediately 
euthanized using 1-2 mL of intravenous pentobarbital sodium (390 mg/mL).  Whole kidneys 
were harvested from each bird and fixed in 10% neutral-buffered formalin.  One kidney from 
each treatment group was chosen randomly for histopathological review.  Tissue samples were 
sectioned into 5 µm cuts and stained with hematoxylin and eosin.   
 
Biochemical Analysis 
A commercially available chemical analyzer was used to obtain albumin, uric acid, and total 
protein levels for each bird from the frozen pre- and post-treatment plasma samples. 
 
Pharmacokinetic Analysis 
Detection of diclofenac concentration in the post-treatment plasma samples from each bird was 
performed using HPLC-MS detection.a  
 
Statistical analysis  
Due to non-parametric distribution, pre- and post-treatment biochemical parameters (albumin, 
uric acid, and total protein) within each group were compared using the Wilcoxon signed-rank 
test. Statistical outliers were identified when data was interpreted with a boxplot graph. P values 
< 0.05 were considered significant. 
 
Plasma diclofenac concentrations between groups 2 and 3 were compared using a one-way 
ANOVA. Linear regression diagnostics and leverage values were utilized to identify outliers. 
 
Results 
Pre- and post-treatment albumin, uric acid, and total protein means for each group are 
summarized in Table 1.  Initial statistical analysis revealed no significant difference between pre- 
and post-treatment total protein or uric acid parameters within any group.  A significant decrease 
in albumin levels was present in post-treatment groups 2 (P = 0.036) and 3 (P = 0.003) when 
compared to pre-treatment values.  Two birds (#22 and #23, both from group 3) were determined 
to be statistical outliers as identified.  Omitting the data from these birds resulted in 
strengthening the significant decrease in post-treatment albumin (P = 0.002).  One of these birds 
(#22) was also considered an outlier when assessing total protein.  Omitting the data point for 
this bird resulted in a significant decrease (P = 0.023) from pre- to post-treatment total protein 
within group 3. 
Post-treatment plasma diclofenac concentrations were undetectable in samples from each bird in 
group 1.  Detectable concentrations of diclofenac were present in all animals from groups 2 and 
3. Results are summarized in Figure 1.  Bird #24 (group 3) was identified as an outlier, but it was 
not influential since drug concentrations in group 3 were significantly greater than group 2 with 
(P = 0.0008) and without (P = 0.0001) including this data point.   
Histopathological examination of the 3 kidneys (1 from each group) showed similar changes.  
Each sample demonstrated hypercellular mesangial regions in one-third to half of the renal 
corpuscles within enlarged glomeruli. The peripheral capillary loops in the enlarged glomeruli 
were distended with a thickened basement membrane.  Hypertrophied podocytes and occasional 
adhesions to Bowman’s capsule were also present. These changes are consistent with chronic 
proliferative glomerulonephritis. 
 
Discussion 
Topical ophthalmic diclofenac administered twice daily to chickens unilaterally or bilaterally for 
one week resulted in detectable plasma levels of drug and minor biochemical alterations.  
Elevation in uric acid and decreases in albumin and total protein have been demonstrated in 
plasma of domestic chickens after administration of oral diclofenac sodium in a previous study.11  
For comparison, the present study evaluated for biochemical evidence of renal pathology by 
monitoring plasma albumin, total protein, and uric acid levels after administration of topical 
ophthalmic diclofenac sodium 0.1% for one week.   
After discarding outliers, significant decreases in post-treatment albumin (P = 0.002) and total 
protein (P = 0.023) were present within the groups treated with diclofenac (groups 2 and 3). A 
statistical difference was not detected for uric acid in any of the 3 groups.  Uric acid is a more 
significant indicator of avian renal pathology than albumin or total protein.25 In the present study, 
although albumin and total protein decreased post-treatment, they were maintained within 
previously published reference intervals.26 
In birds, 90% of uric acid is eliminated via the kidneys and is used in conjunction with clinical 
signs and other diagnostic testing to assess for renal disease.27 Fluctuations in uric acid are 
possible due to extrarenal causes and other confounding factors (species, diet, age, environment, 
ovulatory activity, and laboratory methodology for sample processing), therefore sequential 
evaluation is preferred to evaluate for renal dysfunction.27,28  Ultimately, single-point 
biochemical parameters may raise suspicion for renal pathology, but antemortem diagnosis is 
most accurately made when combining serial clinical pathologic abnormalities with clinical signs 
(lethargy, polyuria, weakness), urinalysis, abdominal imaging, and endoscopic renal 
evaluations.29,30     
Finally, various disease processes decrease albumin while increasing globulin.31 This potentially 
results in the cumulative total protein remaining within a normal reference interval.  The use of 
albumin:globulin ratio has more clinical significance.32  Therefore, the resultant changes in total 
protein and albumin in the present study may not specifically reflect changes in renal function. 
Concentration of diclofenac in plasma was determined using HPLC-MS.  Plasma samples were 
not analyzed for the presence of diclofenac prior to the start of this study due to the history of no 
previous NSAID administration.  Post-treatment samples were negative for diclofenac in control 
birds.  In a review of ophthalmic medications, it was determined that peak plasma concentrations 
of approximately half of the drugs were reached after 15 minutes of topical ophthalmic 
administration in humans.23  Another study reported the time to maximum plasma concentration 
after ophthalmic administration of diclofenac sodium 0.1% was 15 minutes in rabbits.33 
Although the pharmacokinetic profile of topical ophthalmic diclofenac sodium 0.1% in birds has 
not been established, the timing of post-treatment sample collection in the current study was 
determined based on those previous reports.  As expected, diclofenac was detected in group 2 
(mean = 25.4 ± 9.19 ng/mL) and group 3 (mean = 51.3 ± 21.19 ng/mL).   
Biochemical or fatal changes of diclofenac treated birds in previous studies occurred at doses 
ranging from 0.005 mg/kg to 20 mg/kg with Gyps vultures being the most sensitive to 
effects.11,12,14,16-20  Of the studies that utilized chickens, a 2 mg/kg dose caused biochemical, but 
non-lethal, changes.11  If we assume 100% systemic absorption of the diclofenac sodium 
ophthalmic drops (~0.04 mg/drop), the mean per treatment dose of diclofenac for birds in the 
present study would be 0.028 mg/kg and 0.057 mg/kg for the treated groups 2 and 3, 
respectively.  The extent of systemic effects from topically applied ophthalmic diclofenac is 
unknown, however, given the low plasma concentration detected in the present and previous 
studies it is unlikely that a toxic level could be reached in plasma.3,34 
Previous studies demonstrated that sensitivity differences in response to NSAIDs exist between 
avian species.12-14,18  For example, one report determined that although chickens can succumb to 
diclofenac toxicity (50% lethal dose ~10 mg/kg), they are more tolerant of the biochemical 
effects (abnormal renal parameters and acute renal tubular necrosis) compared to Gyps vultures 
(50% lethal dose ~0.1 mg/kg).12,14 Other studies reported the Pied crow (Corvus albus) and 
turkey vulture (Cathartes aura) are not susceptible to diclofenac-induced renal toxicity.12,18 
Although the present study demonstrated the apparent safety of unilateral or bilateral twice daily 
ophthalmic diclofenac administration in chickens, it may not be possible to extrapolate the safety 
of this dose to all avian species. 
Chronic proliferative glomerulonephritis was observed histopathologically in one randomly 
selected sample from each of the three treatment groups.  These lesions differ from the 
glomeruli-sparing acute proximal convoluted tubular necrosis observed in Pakistani vultures 
(Gyps bengalensis) that were naturally and experimentally exposed to diclofenac via ingestion of 
contaminated meat.16,17  Acute renal tubular necrosis has been documented in a variety of other 
avian species after treatment with diclofenac sodium, including the domestic chicken.11,13,14  Due 
to the different region of the kidneys affected (glomeruli versus tubules), and given the control 
group in the present study was also affected; it is unlikely the lesions were caused by diclofenac 
administration. Glomerulonephritis reportedly occurs spontaneously in clinically normal 
chickens, as well as in conjunction with numerous disease processes.35-41  In general, there are 
many etiologic causes for avian renal disease, including viruses, bacteria, parasites, mycotoxins, 
neoplasia, and nutritional imbalances.30,42  Additional testing to attempt to diagnose the 
underlying cause of the chronic glomerulonephritis identified with histopathology was not 
performed in this study and was presumed to be preexisting. No birds exhibited clinical signs of 
disease throughout the duration of the present study, and visceral gout was not observed during 
postmortem examinations. 
Limitations to the present study include a short duration and infrequency of treatment.  When 
treating clinical disease, ophthalmic NSAID dosing may be required several times daily and 
several weeks of treatment may be necessary.4  Increasing the frequency of treatment to four 
times daily in both eyes would likely result in increased systemic absorption of the medication, 
thereby increasing the risk of biochemical effects of the drug.  Additionally, the exact time to 
peak plasma concentration of ophthalmic diclofenac sodium in chickens is unknown, therefore 
higher concentrations of drug may be present before or after the 15 minute collection point used 
in the present study.  Methodology of sample collection and processing must also be considered 
when interpreting results. As was used in the present study, many laboratories use the bromcresol 
green method to test albumin levels. This method has not been validated for avian species and 
uses human albumin for standards and controls.43 Discrepancies between the bromcresol green 
method and gel electrophoresis indicate the latter is the preferred method for determination of 
avian albumin concentrations.44,32,45  Urinalysis to assess renal function can be performed by 
patient catheterization or via collection from fresh droppings.43,46  These techniques require 
anesthesia or housing birds individually which was not feasible in this study.  Financial 
limitations prohibited using gel electrophoresis in the present study.  Additionally, financial 
constraints prohibited histopathologic evaluation of additional kidneys collected at necropsy. 
Finally, a small per group sample size may have led to the abnormally distributed data, which 
prohibited the comparison of biochemical parameters between groups.   
Results of this study indicate topical ophthalmic diclofenac sodium 0.1% was detectable in 
systemic circulation in the domestic chicken at 15 minutes post-administration when 
administered every 12 hours in one or both eyes for one week. Although minor biochemical 
changes were detected, the lack of clinical evidence of renal pathology and lack of 
histopathologic acute tubular necrosis, it was concluded that ophthalmic diclofenac sodium did 
not have negative renal effects in the present study.  Due to the possibility of different 
interspecies response to NSAIDs, further investigation of topical ophthalmic diclofenac sodium 
effects on the more commonly treated domestic bird species (i.e. passerines and pscittacines) is 
warranted. 
FOOTNOTES 
a. Veterinary Diagnostic Laboratory, Iowa State University, Ames, Iowa 
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FIGURE LEGENDS 
Figure 1. Plasma diclofenac concentrations (ng/mL) in healthy adult chickens (Gallus gallus 
domesticus) after administration of unilateral (group 2) or bilateral (group 3) topical ophthalmic 
diclofenac sodium 0.1% solution.  Bird #24, the outlier in group 3, is identified by an open circle 
(°). 
 
TABLES 
Table 1. Mean ± SD values (prior to outlier exclusion) for albumin, total protein and uric acid 
before and after treatment with either artificial tear solution or diclofenac sodium 0.1% 
ophthalmic solution in healthy adult chickens (Gallus gallus domesticus). *Denotes a significant 
difference from pre-treatment value (P = 0.05). Group 1 = control group receiving artificial tear 
solution on the left eye twice daily. Group 2 = treatment group receiving diclofenac sodium 0.1% 
on the left eye twice daily. Group 3 = treatment group receiving diclofenac sodium 0.1% on both 
eyes twice daily. 
Table 1.     
 
Group 1  
(n = 6) 
Group 2 
 (n = 12) 
Group 3  
(n = 12) 
Albumin Pre 1.75 ± 0.105 1.85 ± 0.189 1.95 ± 0.183 
(1.3 - 2.8 g/dL) Post 1.7 ± 0.110 1.78 ± 0.185* 1.83 ± 0.154* 
Total Protein Pre 4.5 ± 0.469 4.84 ± 0.565 5.03 ± 0.563 
(3.3 - 5.5 g/dL) Post 4.77 ± 0.408 4.78 ± 0.555 4.8 ± 0.449 
Uric Acid Pre 4.03 ± 1.496 6.23 ± 5.910 7.41 ± 5.652 
(2.5 - 8.1 mg/dL) Post 3.38 ± 1.291 8.17 ± 9.842 11.18 ± 11.420 
 
 
